Henderson Mary Elizabeth 4

What Happened

• Mary Elizabeth Henderson, Senior Vice President, Technical Operations at Jazz Pharmaceuticals (JAZZ), was credited with 10,116 ordinary shares on January 16, 2026. The Form 4 reports the shares as an award/acquisition (code A) at a reported price of $0.00 (i.e., vested performance award; total reported cash price $0).
• This was not a market purchase or sale — it reflects the vesting/delivery of performance-based restricted shares rather than a trade.

Key Details

• Transaction date: January 16, 2026 (vest date / certification of performance level).
• Reported on SEC Form 4 filed January 21, 2026.
• Amount: 10,116 shares; reported price $0.00 (award vesting).
• Shares owned after the transaction: not specified in the filing.
• Footnote: The shares were granted as performance share awards on March 3, 2023; the performance-based vesting criteria were certified satisfied on January 16, 2026 (footnote F1).
• Filing timing: Form 4 was filed five days after the transaction date (typically Form 4 must be filed within two business days), so this appears later than the usual reporting window.

Context

• Performance-share vesting is a common form of executive compensation and differs from buying or selling shares; it doesn't necessarily signal a change in the insider's market view.
• No immediate sale or tax-withholding transaction was reported in this filing; further filings could report any subsequent sales or withholding related to these shares.